New Data From Amgen To Be Presented At ACC.19 Continues To Build Evidence For Repatha® (evolocumab) Across Multiple Patient Populations Read more about New Data From Amgen To Be Presented At ACC.19 Continues To Build Evidence For Repatha® (evolocumab) Across Multiple Patient Populations
Amgen Announces 2019 Second Quarter Dividend Read more about Amgen Announces 2019 Second Quarter Dividend
Amgen To Present At The Cowen and Company 39th Annual Healthcare Conference Read more about Amgen To Present At The Cowen and Company 39th Annual Healthcare Conference
Amgen Highlights Progress Of Innovative Early Oncology Pipeline With New Data At AACR 2019 Read more about Amgen Highlights Progress Of Innovative Early Oncology Pipeline With New Data At AACR 2019
Jury Upholds Amgen's Patents On Repatha® (evolocumab) Read more about Jury Upholds Amgen's Patents On Repatha® (evolocumab)
Amgen, Cytokinetics And Servier Announce Start Of METEORIC-HF, The Second Phase 3 Clinical Trial Of Omecamtiv Mecarbil In Patients With Heart Failure Read more about Amgen, Cytokinetics And Servier Announce Start Of METEORIC-HF, The Second Phase 3 Clinical Trial Of Omecamtiv Mecarbil In Patients With Heart Failure
Amgen Reports Fourth Quarter And Full Year 2018 Financial Results Read more about Amgen Reports Fourth Quarter And Full Year 2018 Financial Results
Amgen Announces Webcast of 2018 Fourth Quarter and Full Year Financial Results Read more about Amgen Announces Webcast of 2018 Fourth Quarter and Full Year Financial Results
Amgen Receives NMPA Approval For Repatha® (evolocumab) In China To Reduce The Risk Of Cardiovascular Events Read more about Amgen Receives NMPA Approval For Repatha® (evolocumab) In China To Reduce The Risk Of Cardiovascular Events
Amgen And Allergan Announce Positive Top-Line Results From Phase 1/ Phase 3 Study Of ABP 798, Biosimilar Candidate To Rituximab Read more about Amgen And Allergan Announce Positive Top-Line Results From Phase 1/ Phase 3 Study Of ABP 798, Biosimilar Candidate To Rituximab
